RecruitingNCT07196033

Asian Gynecological Brachytherapy Registry in Cervical Cancer


Sponsor

Tata Memorial Hospital

Enrollment

1,000 participants

Start Date

Feb 20, 2026

Study Type

OBSERVATIONAL

Conditions

Summary

Gynecological cancer poses as significant public health issue, especially in Asian countries, where it is a leading cause of cancer-related deaths among women. Cervical cancer accounts for around 311,000 deaths annually, with over 85% occurring in low- and middle-income nations, primarily in Asia. Factors contributing to this burden include limited access to preventive care, inadequate screening, high rates of human papillomavirus infection, and cultural barriers that delay medical attention. For patients with advanced cervical cancer, the standard treatment involves external beam radiation therapy along with chemotherapy followed by internal radiation, known as Brachytherapy. This technique uses unique set of devices placed internally at the tumor sitegiving localized radiation to the residual tumor tissue. While advanced brachytherapy techniques have been developed and practiced in Europe and American countries yielding excellent clinical outcomes, there is insufficient data on the use and results of such advanced brachytherapy techniques in Asian populations, leading to a lack of standardized practices. To address these issues, the Asian Gynecological Brachytherapy Registry (ABGR) has been established as a collaborative platform for data collection and analysis on the use of Brachytherapy techniques. This registry aims to consolidate information from various healthcare settings across Asia, enhancing understanding of cervical cancer's epidemiology, evaluating treatment effectiveness, and identifying areas for improvement in patient care.


Eligibility

Sex: FEMALE

Plain Language Summary

Simplified for easier understanding

This registry study is collecting data from across Asian cancer centers about how gynecological brachytherapy — a form of internal radiation placed directly inside or near the cervix — is delivered and how it affects outcomes for patients with cervical cancer. **You may be eligible if...** - You have been diagnosed with cervical cancer (FIGO 2018 stage IB to IVA) with squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma - Your treatment plan includes definitive chemoradiation combined with brachytherapy (internal radiation) **You may NOT be eligible if...** - Your cervical cancer is a rare histologic type such as neuroendocrine cancer - Your cancer has spread beyond the pelvis (metastatic) and you are not planned for radical (curative-intent) radiation doses - You are receiving radiation after surgery or for cancer that has come back (recurrent disease) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(5)

Tata Memorial Center

Mumbai, Maharashtra, India

Gunma University

Maebashi, Japan, Japan

Juntendo University

Tokyo, Japan, Japan

Mahidol University

Bangkok, Thailand, Thailand

Chiang Mai University

Chiang Mai, Thailand, Thailand

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07196033


Related Trials